Cleveland Diagnostics Company Profile
Background
Overview
Cleveland Diagnostics is a commercial-stage biotechnology company specializing in the development of advanced diagnostic tests for the early detection of cancers. Founded in 2013 and headquartered in Cleveland, Ohio, the company leverages its proprietary IsoClear™ platform to create non-invasive, lab-friendly, and affordable diagnostic solutions. Their mission is to assist physicians and patients in detecting cancer early, when it is most treatable and survivable. The company's vision is to make cancer diagnoses less feared by providing more definitive insights earlier, enabling critical and potentially lifesaving decisions.
Industry Significance
Cleveland Diagnostics operates within the biotechnology sector, focusing on oncology diagnostics. The company's innovative approach addresses the significant challenge of early cancer detection, aiming to reduce unnecessary procedures and improve patient outcomes. By offering more accurate and accessible diagnostic tests, Cleveland Diagnostics contributes to the advancement of personalized medicine and the optimization of healthcare resources.
Key Strategic Focus
Core Objectives
The company's primary objective is to develop and commercialize diagnostic tests that enhance the early detection of cancers, thereby improving treatment outcomes and reducing healthcare costs.
Areas of Specialization
Cleveland Diagnostics specializes in the development of non-invasive blood tests that analyze protein biomarkers at the structural level, providing insights into the presence and aggressiveness of cancer.
Key Technologies Utilized
The IsoClear™ platform is central to the company's technology suite. This platform employs Solvent Interaction Analysis™ (SIA) to investigate protein biomarkers, offering a more direct understanding of the protein's origin at the cellular level, thus enhancing test specificity to the underlying disease process.
Primary Markets Targeted
Cleveland Diagnostics primarily targets the oncology diagnostics market, focusing on early detection tests for prostate, breast, and lung cancers, as well as certain neurological diseases.
Financials and Funding
Funding History
As of April 2026, Cleveland Diagnostics has raised a total of $111.49 million across multiple funding rounds. The most recent funding round was a Series E - II round, raising $14.42 million in December 2025.
Notable Investors
Key investors include Novo Holdings, LYFE Capital, and the Cleveland Clinic.
Utilization of Capital
The capital raised is intended to support the commercialization of the IsoPSA assay, expand the company's diagnostic portfolio, and enhance research and development efforts to advance early cancer detection technologies.
Pipeline Development
Key Pipeline Candidates
- IsoPSA Assay: A blood-based test designed to improve the detection of high-grade prostate cancer and reduce unnecessary biopsies.
Stages of Development
The IsoPSA assay has received FDA premarket approval, allowing for its distribution as an in vitro diagnostic kit to clinical laboratories nationwide.
Target Conditions
The primary focus is on prostate cancer, with plans to expand the diagnostic portfolio to include breast and lung cancers, as well as certain neurological diseases.
Anticipated Milestones
The company aims to achieve broader clinical adoption of the IsoPSA assay, expand its product offerings, and continue to innovate in the field of early cancer detection.
Technological Platform and Innovation
Proprietary Technologies
- IsoClear™ Platform: Utilizes Solvent Interaction Analysis™ (SIA) to analyze protein biomarkers at the structural level, enhancing diagnostic specificity.
Significant Scientific Methods
- Solvent Interaction Analysis™ (SIA): A method that examines protein biomarkers' structural differences to determine their origin, improving test accuracy.
Leadership Team
Executive Management Team
- Michael Iskra: Chief Executive Officer
Professional Background: Over 30 years of experience in the diagnostics industry, including leadership roles at Bayer, Siemens, and QuidelOrtho.
Key Contributions: Appointed CEO in January 2026 to drive strategic growth following FDA approval of the IsoPSA assay.
- Arnon Chait, PhD, MBA: Chief Innovation Officer
Professional Background: Co-founder of Cleveland Diagnostics with expertise in protein chemistry and cancer diagnostics.
Key Contributions: Led the development of the IsoClear™ platform and the IsoPSA assay.
- Aimee Kestranek: Chief Operating Officer
Professional Background: Extensive experience in operations management within the biotechnology sector.
Key Contributions: Oversees daily operations and strategic initiatives to ensure efficient company performance.
- Bob Rochelle, MBA: Chief Commercial Officer
Professional Background: Background in commercial strategy and business development in healthcare.
Key Contributions: Responsible for driving market adoption and commercialization strategies for Cleveland Diagnostics' products.
- Mark Stovsky, MD, MBA, FACS: Chief Medical Officer
Professional Background: Board-certified urologist with expertise in oncology and medical affairs.
Key Contributions: Provides medical leadership and guidance on clinical development and regulatory strategies.
Board of Directors
- Jack Kenny: Chair of the Board
Professional Background: Former CEO of Meridian Bioscience.
Key Contributions: Provides strategic oversight and guidance to the company's leadership team.
- Dara Grantham Wright: CEO of Madison Medical
Professional Background: Leadership experience in medical device and diagnostics companies.
Key Contributions: Offers expertise in medical technology commercialization and market expansion.
- Noel Jee, PhD: Partner at Novo Holdings
Professional Background: Investment professional with a focus on healthcare and biotechnology sectors.
Key Contributions: Provides strategic investment insights and guidance to the board.
- Joseph Rich, JD, MBA: Managing Partner, Innovations and Ventures at Cleveland Clinic
Professional Background: Expertise in healthcare innovation and venture capital.
Key Contributions: Offers guidance on strategic partnerships and innovation initiatives.
- Sameer Rohatgi: Partner at LYFE Capital
Professional Background: Investment professional with a focus on healthcare and life sciences.
Key Contributions: Provides strategic investment perspectives and supports the company's growth initiatives.
Competitor Profile
Market Insights and Dynamics
The oncology diagnostics market is experiencing significant growth, driven by the increasing prevalence of cancer and the demand for early detection methods. Advancements in biomarker research and the adoption of non-invasive testing are key trends shaping the industry.
Competitor Analysis
- Novigenix: Specializes in immuno-oncology diagnostics, offering tests that assess the immune response to cancer.
- OpGen: Focuses on molecular diagnostics and precision medicine, providing tests for infectious diseases and oncology.
- Biocept: Develops liquid biopsy tests for the detection of cancer-related genetic mutations and alterations.
Strategic Collaborations and Partnerships
Cleveland Diagnostics has established strategic partnerships with leading healthcare institutions, including the Cleveland Clinic, to enhance research and development efforts and expand market reach.
Operational Insights
Cleveland Diagnostics differentiates itself through its proprietary IsoClear™ platform, which offers a unique approach to protein biomarker analysis, providing higher specificity and sensitivity compared to traditional methods. This technological edge positions the company favorably in the competitive landscape.
Strategic Opportunities and Future Directions
The company plans to expand its diagnostic portfolio to include tests for breast and lung cancers, as well as certain neurological diseases.
